Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.8179
+0.0899 (12.35%)
At close: Feb 19, 2026, 4:00 PM EST
0.7900
-0.0279 (-3.41%)
After-hours: Feb 19, 2026, 5:16 PM EST
Aprea Therapeutics Revenue
Aprea Therapeutics had revenue of $1.85K in the quarter ending September 30, 2025, a decrease of -99.48%. This brings the company's revenue in the last twelve months to $488.24K, down -62.75% year-over-year. In the year 2024, Aprea Therapeutics had annual revenue of $1.50M with 157.63% growth.
Revenue (ttm)
$488.24K
Revenue Growth
-62.75%
P/S Ratio
10.43
Revenue / Employee
$61,030
Employees
8
Market Cap
5.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.50M | 919.35K | 157.63% |
| Dec 31, 2023 | 583.23K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 2.86M |
| Cyclerion Therapeutics | 2.86M |
| 60 Degrees Pharmaceuticals | 1.36M |
| Bio Green Med Solution | 81.00K |
| Silo Pharma | 72.10K |
APRE News
- 1 day ago - Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars - Benzinga
- 1 day ago - Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial - GlobeNewsWire
- 2 days ago - Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 7 days ago - Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth - GlobeNewsWire
- 15 days ago - Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor - GlobeNewsWire
- 21 days ago - Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan - GlobeNewsWire
- 21 days ago - Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 - GlobeNewsWire